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ABSTRACT  
Cardiovascular diseases (CVD) are a major public health problem. Disruption of trace 
element homeostasis may lead to oxidative stress, and consequent DNA damage, lipid 
peroxidation, protein modification and other biochemical effects, causing CVD. The 
main goal of this work was to directly study the disease-related changes on some trace 
elements levels (Cu, Cd, Pb, Se and Zn) in different tissues: kidney (medulla and 
cortex) and aorta (with and without atheroma plaque). 
Comparing the two kidney regions, higher levels were found in cortex, but the 
difference reached statistical significance only for Zn (166.1±100.2 vs 115.7±86.5 µg/g; 
p≤0.01) and Cd (72.57±45.43 vs 41.37±38.72 µg/g; p≤0.0001). For kidney medulla, a 
gender-related difference was found for Pb, with higher levels in men (0.32±0.23 µg/g) 
than women (0.16±0.10 µg/g; p≤0.01). It was also observed that smoking habits have 
an influence in some trace elements levels in this kidney structure. Higher levels of Zn 
(16671±112.1 vs 91.46±63.47 µg/g; p≤0.01), Cd (75.97±61.04 vs 27.78±20.24 µg/g; 
p≤0,001) and Pb (0.39±0.19 vs 0.21±0.20 µg/g; p≤0.05) were found in smokers. In 
kidney cortex no significant difference was found between genders for any of the five 
elements studied. Regarding smoking habits, only Cd showed a significant difference 
between smokers (110.1±37.74 µg/g) and non-smokers (51.06±27.62 µg/g; p≤0.0001). 
In both kidney regions, a slight tendency for an age-related increase was observed for 
the five elements. However, the Cd levels in renal cortex only increased up to 50 years 
old; then a subsequent decrease was observed. 
In aorta without plaque no significant gender- or smoking habits-related differences 
were found for any of five elements. In aorta with plaque, smokers showed significantly 
decreased Zn levels: 78.44±32.25 µg/g vs 126.45±66.60 µg/g in non-smokers (p≤0.05). 
When comparing both tissues (aorta with and without plaque), increased levels of Zn 
and decreased levels of Se were found in aorta with plaque (110.9±58.42 vs 
89.74±28.45 µg/g; p≤0,05 and 3.85±2.50 vs 4.71±2.33 µg/g; p≤0,01, respectively). In 
aorta without plaque only Pb showed to be related (increased) with age. In aorta with 
plaque, an age-related tendency for decreased levels was observed for Cu, Cd and Se. 
On the contrary, Zn and Pb showed a tendency to increase with age. 
Individuals with CVD showed significantly lower levels of Cu and Se in both tissues – 
Cu kidney: 5.61±3.82 vs 7.96±3.71 µg/g; Cu aorta: 3.18±1.32 vs 4.48±2.69 µg/g; Se 
kidney: 3.90±2.80 vs 5.48±5.35 µg/g; Se aorta 3.59±2.45 vs 4.46±2.14 µg/g). 
Interestingly, decreased levels of Cd and Pb were also observed.  
Keywords: Trace elements; cardiovascular diseases; ICP-MS; postmortem analysis; 
kidney; aorta.  
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RESUMO  
As doenças cardiovasculares (DCVs) são um sério problema de saúde pública. A perturbação 
da homeostase dos elementos vestigiais pode levar a stress oxidativo e consequente dano no 
ADN, peroxidação lipídica e modificação de proteínas, entre outros efeitos bioquímicos, 
causando DCV. O principal objetivo deste trabalho foi estudar diretamente as alterações, 
relacionadas com as DCVs, nos níveis de alguns elementos vestigiais (Cu, Cd, Pb, Se e Zn) 
em diferentes tecidos: rim (medula e córtex) e aorta (com e sem placa de ateroma). 
Comparando as duas regiões do rim, foram encontrados níveis mais elevados no córtex, mas 
a diferença só foi estatisticamente significativa para Zn (166,1±100,2 vs 115,7±86,5 µg/g; 
p≤0,01) e Cd (72,57±45,43 vs 41,37±38,72 µg/g; p≤0,0001). Em relação à medula renal, foi 
observada uma diferença entre sexos para o Pb, com níveis mais elevados nos homens 
(0,32±0,23 µg/g, vs 0,16±0,10 µg/g nas mulheres; p≤0,01). Observou-se também que o 
tabagismo influencia os níveis de alguns elementos nesta região do rim. Nos fumadores foram 
encontrados níveis mais elevados de Zn (166.73±112.1 vs 91.74±63.47 µg/g; p≤0.01), Cd 
(75.97±61.04 vs 27.78±20.24 µg/g; p≤0,001) e Pb (0,39±0,19 vs 0,21±0,205 µg/g; p≤0.05). No 
córtex renal não foram encontradas diferenças significativas entre sexos para qualquer dos 
cinco elementos estudados. Em relação ao tabagismo, somente o Cd mostrou uma diferença 
significativa entre fumadores (110,1±37,74 µg/g) e não fumadores (51,06±27,62 µg/g; 
p≤0.0001). Em ambas as regiões do rim, foi observada uma ligeira tendência para um 
aumento relacionado com a idade nos níveis dos cinco elementos. No entanto, os níveis de 
Cd no córtex renal aumentaram somente até aos 50 anos de idade, diminuindo depois.  
Na aorta sem placa não foram encontradas diferenças significativas entre sexos ou 
relacionadas com os hábitos tabágicos para qualquer dos cinco elementos. Na aorta com 
placa, os fumadores apresentaram uma diminuição significativa dos níveis de Zn: 78,44±32,25 
vs 126,45±66,60 µg/g em não-fumadores (p≤0,05). Na comparação entre os tecidos (aorta 
com e sem placa), foi observado um aumento significativo dos níveis de Zn e uma diminuição 
dos níveis de Se na aorta com placa (110.9±58.42 vs 89.74±28.45 µg/g; p≤0.05 e 3.85±2.50 
vs 4.71±2,34 µg/g; p≤0.01, respetivamente). Na aorta sem placa só o Pb mostrou estar 
relacionado (aumentado) com a idade. Na aorta com placa observou-se uma tendência para a 
diminuição com a idade dos níveis de Cu, Cd e Se. Pelo contrário, o Zn e o Pb mostraram 
uma tendência para aumentarem com a idade. 
Os indivíduos com DCV apresentaram níveis significativamente mais baixos de Cu e Se em 
ambos os tecidos – Cu renal: 5.61±3.82 vs 7.96±3.71 µg/g; Cu aorta: 3.18±1.32 vs 4.48 ± 2.69 
µg/g; Se renal: 3.90±2.80 vs 5.48±5.35 µg/g; Se aorta 3.19±1,60 vs 4.00±1.53 µg/g). 
Curiosamente, também foi observada uma diminuição dos níveis de Cd e Pb. 
Palavras-chave: Elementos vestigiais; doenças cardiovasculares; ICP-MS; análise 
postmortem; rim; aorta. 
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THEORETICAL BACKGROUND 
  
2 
 
1.1  INTRODUCTORY NOTE  
The aging of population in developed countries resulted in an increase in longevity. In 
some developed countries, where these increase of longevity began in the early twentieth 
century, more than 15% of the population has 65 years or more, and 3-4% of the 
population is 80 years old or over. European countries have the highest proportion of 
elderly people worldwide: about 14% of people in Western Europe have ≥ 65 years. In this 
sense, Sweden may be considered the country with the highest rate of longevity in the 
world, with 18% of its population aged ≥ 65 years (1). 
According to WHO (World Health Organization), the average life expectancy in the world 
will reach 73 years in 2025. This increase corresponds to a decline in infant mortality in 
general and the decline of fertility rates. Such acute changes in population structure 
decreased the time available to and increased the resources needed to expand the 
infrastructure of health, already overburdened, to face chronic diseases, increasingly 
prevalent in older adults, including cardiovascular diseases, that appear prominently (2). 
Portugal is no exception to this scenario. According to INE (National Statistics Institute) 
the proportion of young people (population under 15 years old) decreased to 15% and the 
elderly (people aged 65 years or over) increased to 19% between 2001 and 2011. The 
population aged 65 years or over residing in Portugal will increase from 2.033 to 3.043 
million between 2012 and 2060 (3). 
Cardiovascular diseases (CVD) are a major public health problem worldwide and are 
responsible for almost half of all deaths in Europe (4). Studies indicate that over 80% of 
CVD mortality occurs in individuals over the age of 65. 
Atherosclerosis is considered an inflammatory process, and there are clinical, 
epidemiological and experimental studies which evidence that oxidative stress is a key-
factor on its development and progression (5). 
In this context, several theories exist suggesting that substances endowed with 
antioxidant properties, particularly some trace elements (e.g., Cu, Se), could have a 
protective effect on the development of atherosclerotic disease. 
However, despite their wide dissemination, this "antioxidant" hypothesis is far from an 
absolutely established stand and it has been difficult to study the specific impact of dietary 
intake of trace elements and the correlation of blood levels with cardiovascular morbidity 
and mortality. More specifically, the extent to which changes in blood levels are reflected 
in the tissues is not clear. 
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A potentially more informative approach to this issue would be by directly studying the 
levels of trace elements in organs and target tissues (6-8). 
In this context, the main objective of the work we proposed to develop was to study the 
possible involvement of trace elements – both “essential” (Zn, Cu, Se) and "toxic" (Cd, Pb) 
in atherosclerosis and CVD. 
Most of the existing studies on this topic are based on the analysis of body fluids such as 
blood and urine because they can be collected easily. In this work the direct analysis of 
tissues (kidney and aorta), collected during autopsy exams, was performed. 
To this end, the most appropriate analytical procedures were used: a closed vessel acid 
digestion in a microwave oven (a process very efficient and that ensures maximum 
protection of the samples from loss and/or contamination), for samples solubilization; and 
ICP-MS (inductively coupled plasma-mass spectrometry), an analytical instrumental 
technique that is essentially characterized by its high sensitivity and multi-element 
analysis capability, for the analysis of the resulting solutions. 
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1.2  CARDIOVASCULAR DISEASES 
CVD are the leading cause of morbidity and mortality in developed countries, accounting 
for over a third of all deaths (9). According to WHO (10), CVD are a group of diseases of 
the heart and blood vessels comprising: 
1. CVD due to atherosclerosis: 
 Ischaemic heart disease or coronary artery disease (e.g. heart attack) 
 Cerebrovascular disease (e.g. stroke) 
 Diseases of the aorta and arteries, including hypertension and peripheral vascular 
disease 
2. Other CVD 
 Congenital heart disease 
 Rheumatic heart disease 
 Cardiomyopathies 
 Cardiac arrhythmias 
Myocardial infarctions (“heart attack”) and stroke are usually acute events and are mainly 
caused by a blockage that stops blood from flowing to the heart or the brain. The most 
common cause is the formation of fatty deposits on the inner walls of blood vessels. 
Strokes may be caused by bleeding from a blood vessel in the brain (hemorrhagic stroke) 
or by a vessel blockade due to a blood clot (ischemic stroke). 
Rheumatic heart disease is caused by damage to the heart muscle and heart valves from 
rheumatic fever. Malformations of heart structures present at birth are known as 
congenital heart defects. They may be caused by: (i) a close blood relation between 
parents (consanguinity); (ii) maternal infections (e.g. rubella); (iii) maternal abuse of 
alcohol and drugs (e.g. warfarin); and (iv) poor maternal nutrition (e.g. deficiency of folic 
acid). In some cases the cause remains unknown. Examples of congenital heart disease 
include holes in the septum of the heart, abnormal valves and abnormalities in heart 
chambers (10).  
Other CVD, such as disorders of the electrical conduction system of the heart (e.g. 
cardiac arrhythmias), disorders of the heart muscle (e.g. cardiomyopathy) and heart valve 
diseases are less common than heart attacks and strokes. 
The costs of CVD are one of the higher, in the different group of diagnosis. Thus, 
prevention and minimization of the various risk factors, may be the most effective means 
of preventing clinical events during the life (11). 
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The American Heart Association (AHA) has established a new concept, the "ideal 
cardiovascular health”, which emphasizes seven positive behaviours and the factors that 
increase the likelihood of living free of CVD, and stroke in particular. This concept consists 
in: 
1. Simultaneous presence of four healthy behaviours: a) abstinence from smoking in the 
last year; b) ideal body mass index (BMI); c) physical activity; d) a dietary pattern that 
promotes cardiovascular health; 
2. Simultaneous presence of three factors: a) total cholesterol less than 200 mg/dL; b) 
arterial blood pressure lower than 120/80 mmHg; c) absence of diabetes mellitus; 
3. No clinically established CVD (e.g., coronary artery disease, stroke). 
1.2.1 Arteriosclerosis 
Arteriosclerosis is a general term for the thickening and hardening of arteries. Due to the 
decreased elasticity of the arterial wall, systolic blood pressure increases and the diastolic 
blood pressure decreases. Arteriosclerosis is almost universally present in the elderly and 
it is more prevalent in males (12).  
1.2.2 Atherosclerosis 
Atherosclerosis is a type of arteriosclerosis. It is an inflammatory disease (13). 
Atherosclerotic lesions are often found in the aorta and major aortic branches. They are 
also common in the coronary arteries, where the condition is called “coronary artery 
disease” (also called coronary heart disease or ischemic heart disease).  
The underlying pathology is characterized by a chronic inflammatory process of the 
arterial wall which disturbed the blood laminar flow, particularly at the branch points (14). 
On initiation of an atherogenic diet, rich in cholesterol and saturated fat, one of the first 
ultra-structural alterations is the accumulation of small lipoprotein particles in the intima. 
The binding of lipoproteins to proteoglycan in the intima captures and retains these 
particles, accounting for their prolonged residence time. Lipoprotein particles bound to 
proteoglycan seems to exhibit increased susceptibility to oxidative or other chemical 
modifications, considered by many to be an important component of the pathogenesis of 
early atherosclerosis (2).  
The second morphologically definable event in the initiation of atheroma (a mass or 
plaque of degenerated thickened arterial intima, occurring in atherosclerosis) is leukocyte 
recruitment and accumulation. Under normal conditions, endothelial cells inhibit leukocyte 
adhesion to the vascular surface. However, early after initiation of hypercholesterolemia, 
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leukocytes adhere to the vascular surface and begin to accumulate lipids and transform 
into “foam cells”. Via secretion of cytokines, leukocytes penetrate the endothelial cell and 
enter the arterial wall (2).  
Whereas the early events in atheroma initiation involve primarily altered endothelial 
function and recruitment and accumulation of leukocytes, the subsequent evolution of 
atheroma into more complex plaques involves migration of circulating monocytes, T cells 
and smooth muscle cells from the media, leading to an accumulation of these cells within 
the vascular intima. In addition, smooth muscle cell death may also participate in 
complication of the atherosclerotic plaque (2). 
Plaques often develop areas of calcification as they evolve. Some subpopulations of 
smooth muscle cells may foster calcification by enhanced secretion of cytokines such as 
bone morphogenetic proteins, homologues of TGF-beta (2). 
These lesions (atheromatous plaques) enlarge as cells and lipids accumulate and begin to 
bulge into the vessel lumen (Figure 1). When the process continues, there is thinning of 
the fibrous cap accompanied by fissuring of the endothelial surface of the plaque, which 
may rupture. With the rupture of the plaque, lipid fragments and cellular debris are 
released into the vessel lumen. These are exposed to thrombogenic agents on the 
endothelial surface, resulting in the formation of a thrombus. If the thrombus is large 
enough, and a coronary blood vessel or a cerebral blood vessel is blocked, this results in 
a heart attack or a stroke (10). 
Atherosclerosis is clinically manifested in 10% of the population over 50 years, its 
development is slow and progressive, and significant arterial obstruction is needed, about 
75% of the caliber of an artery, to lead to early ischemic symptoms (12). 
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Figure 1  Normal artery (left) and an artery affected by atherosclerosis (right). 
Certain drugs can reduce the risk associated with atherosclerosis. These include statins, 
which reduce the level of cholesterol and other fats in the blood, as well as anticoagulant 
drugs such as aspirin that prevent the formation of blood clots. In large arteries such as 
the aorta or carotid, the sections blocked by atheroma plaques may be surgically removed 
and replaced by synthetic materials. They can also be removed by atherectomy, in which 
fatty deposits are removed carefully using a blade inserted into the vessel through a 
catheter. In the case of completely obstructed coronary arteries, the lives of patients have 
been saved through coronary artery bypass surgery, in which sections of blood vessels 
from other parts of the body are used to divert blood flow around the blockages. Some 
occlusions can be opened by balloon angioplasty, in which a catheter is inserted into the 
site of the obstruction and a balloon is inflated in order to dilate the artery and flatten the 
deposits (atherosclerotic plaques) (15). 
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1.3  RISK FACTORS 
Risk factor is a particular condition which is associated with increased probability of an 
individual to suffer or die from a disease. The knowledge of risk factors allows then to 
predict, determine the aetiology, diagnose or prevent the disease (16). 
The rate of progression of atherosclerosis is influenced by cardiovascular risk factors. A 
classic classification of cardiovascular risk factors (CRF) is based on the possibility of the 
patient to modify them or not. The modifiable risk factors are those that can be changed 
through the adoption of new behaviours or lifestyles: hypertension (HT), diabetes mellitus 
(DM), hypercholesterolemia, dyslipidaemia, obesity, smoking, sedentary lifestyle, dietary 
habits, alcoholism, stress and others. The non-modifiable risk factors are those that do not 
depend on the will of the individual, so they cannot be changed, such as gender, age, 
previous personal history and family history. According to WHO, 75% of CVD can be 
attributed to modifiable risk factors (16).  
Table 1  Modifiable and non-modifiable risk factors for cardiovascular disease.  
Modifiable risk factors  Non-modifiable risk factors 
Hypertension Gender 
Diabetes mellitus Age 
Hypercholesterolemia Previous history 
Dyslipidaemia Family history 
Obesity  
Smoking  
Sedentary  
Eating habits  
Alcoholism  
Stress  
 
1.3.1 Age 
Of all the risk factors, age showed to have the strongest and most consistent association 
with CVD (17). Studies indicate that the incidence of stroke increases exponentially from 
50-60 years and more than 80% of CVD mortality occurs in individuals older than 65 years 
(18, 19). As age advances, there is an increase in intimal thickening of arteries by diffuse 
accumulation of smooth muscle cells, connective tissue, decreased elastin and gradual 
increase in the stiffness of the vessels. The weakness of the arterial wall is recognized as 
a phenomenon that increases with age, especially after age 60 (17, 18).  
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1.3.2 Hypertension 
Worldwide, approximately 62% of strokes and 49% of cases of coronary heart disease 
(CHD) are attributed to a higher blood pressure (> 115 mmHg systolic), a factor that 
accounts for more than 7 million deaths per year (2). According to the study by Lawes et 
al. (20), it is estimated that about 14% of deaths and 6% of disability-adjusted life years 
(DALY)1 are caused by a non-optimal blood pressure.  
When blood pressure rises, the resistance to the expulsion of the blood increases and the 
heart, to move the same volume of blood, is subject to a larger effort. To address this 
situation the heart has adaptation mechanisms, which is the cardiac hypertrophy. The 
heart is able to gradually increase the thickness of its walls, thereby increasing the force 
with which it contracts. However, there are limits, and permanently increased arterial 
resistance causes the heart to fail after a few years, exceeding its resilience and 
adaptability. Then, heart begins to dilate and stops working as efficiently, moving into a 
period of incapacity to promote adequate blood flow to the body's needs, thus resulting in 
heart failure. This mechanism is just one of the dangers of hypertension. The other one is 
the fact that hypertension functions as risk factors for atherosclerosis. Thus, excessive 
pressure in the arteries favors the deposition of fat in the walls and the consequent 
development of atherosclerosis. And the greater the values of blood pressure, especially 
the "minimum" (diastolic), the higher is the probability of appearance of lesions and their 
complications, the most common being the stroke and heart attacks, as mentioned above. 
If hypertension is associated with other factors (smoking habits, increased blood fats, 
diabetes, etc.) the risk increases much more (21).  
Blood pressure levels have been shown to be positively and progressively related to the 
risk of stroke and coronary heart disease. In some age groups, the risk of CVD doubles 
for each increase of 20/10 mmHg on blood pressure, starting as low as 115/75 mmHg. In 
addition to coronary heart disease and cerebrovascular disease, uncontrolled blood 
pressure causes heart failure, renal impairment, peripheral vascular disease, damage to 
retinal blood vessels and visual impairment (10). 
The stroke and heart attack risk of people with high cardiovascular risk and/or raised 
blood pressure can be reduced through non-pharmacological (e.g. low salt diet, physical 
activity) and pharmacological measures. These measures are particularly important for 
people with diabetes, as they are also particularly vulnerable to heart attacks and strokes 
                                                          
1 In practice, the sum of years lost due to premature mortality and years lived with disability, adjusted for the 
severity of the disease. 
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(10). Policies to reduce salt consumption can shift the population distribution of blood 
pressure so that there is a reduction in cardiovascular risk. 
1.3.3 Tobacco 
Smoking is estimated to cause nearly 10% of CVD. There is a large body of evidence 
from prospective cohort studies regarding the beneficial effect of smoking cessation on 
coronary heart disease mortality. A 50-year follow-up of British doctors demonstrated that, 
among ex-smokers, the age of quitting has a major impact on survival prospects: those 
who quit between 35 and 44 years of age had the same survival rates as those who had 
never smoked (10). 
Tobacco use is the leading preventable cause of death. Almost 6 million people die from 
tobacco use and exposure each year, accounting for 6% of all female and 12% of all male 
deaths in the world. “Second hand smoke” is also well established as a cause of coronary 
heart disease (2).  
Tobacco is certainly incriminated as a causative factor for atherosclerosis. The combined 
action of nicotine and carbon monoxide results in the onset of atherosclerosis, especially 
coronary atherosclerosis. Nicotine causes increased heart work and carbon monoxide 
decreases the oxygen available, which leads to the possibility of arrhythmias and sudden 
cardiac death (21). 
1.3.4 Dietary habits  
There is a considerable body of evidence regarding the nutritional background of 
atherosclerosis in general and coronary heart disease in particular. High dietary intakes of 
saturated fat, cholesterol and salt, and low intake of fruits, vegetables and fish are linked 
to cardiovascular risk (10). 
Worldwide, high levels of cholesterol cause about 56% of ischemic heart disease and 
18% of stroke, a total of 4.4 million deaths annually. Changes in lifestyle that accompany 
urbanization clearly play an important role, since plasma cholesterol levels tend to be 
higher in the urban than in the rural population. These changes are largely due to the 
increased dietary consumption of fat, especially animal products and processed vegetable 
oils, and decreased physical activity (2).  
The amount of dietary salt consumed is an important determinant of blood pressure levels 
and overall cardiovascular risk. In order to help the prevention of CVD, WHO recommends 
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a population salt intake of less than 5 grams/person/day. Adequate consumption of fruit 
and vegetables reduces the risk of CVD (10). 
High consumption of saturated fats and trans-fatty acids is linked to heart disease; 
elimination of trans-fat and replacement of saturated with polyunsaturated vegetable oils 
lowers coronary heart disease risk (10). 
The increase of cholesterol and lipid levels in blood contributes to the development of 
atherosclerosis and thus coronary disease. It is the increase in blood cholesterol that 
leads to the penetration and deposition in the inner layers of the arterial wall, this 
phenomenon being greater the higher is the concentration of cholesterol in blood (21). 
Thus, the number of people who fall ill and die from coronary disease correlates perfectly 
with cholesterol values. Individuals with a cholesterol level higher than 300 mg/dL have a 
risk of developing CVD four times higher than individuals with cholesterol concentrations 
below 200 mg/dL (21). 
A healthy diet can contribute to a healthy body weight, a desirable lipid profile and a 
desirable blood pressure (10). 
1.3.5 Obesity 
Obesity is a cardiovascular risk factor closely linked to diet and physical inactivity. Obesity 
results when there is an imbalance between energy intake in the diet and energy 
expenditure. Regular physical activity can prevent obesity by increasing the expended 
energy (10). 
Worldwide, at least 2.8 million people die each year as a result of being overweight or 
obese, and an estimated 35.8 million (2.3%) of global DALYs are caused by overweight or 
obesity (10). Obesity is a major risk factor for CVD in adults (4).  
Overweight and obesity are associated with numerous co-morbidities, such as CVD, type 
2 diabetes and certain cancers. The rising prevalence of obesity represents a global 
public health issue, with an estimated 30% of CHD and ischaemic stroke and almost 60% 
of hypertensive disease in developed countries being attributable to increased BMI (4). 
CHD is more frequent in obese people, and the risk increases with the degree of 
overweight. Obesity is often associated with high blood pressure, diabetes and increased 
levels of fats and uric acid in the blood. The very marked obesity also causes other 
cardiac problems. In particular, it requires a permanent increase of heart work that leads 
to hypertrophy, dilatation and onset of heart failure (21). 
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To achieve optimal health, the median BMI for adult populations should be in the range of 
21-23 kg/m2, while the goal for individuals should be to maintain a BMI in the range 18.5-
24.9 kg/m2. 
1.3.6 Diabetes 
Diabetes is a major risk factor for CVD. Diabetes is defined as having a fasting plasma 
glucose value ≥7.0 mmol/L (126 mg/dL). Impaired glucose tolerance and impaired fasting 
glycaemia are an important risk for future development of CVD (10). 
DM affects approximately 180 million people worldwide, and it is estimated that this 
number could double by 2030. Most cases are in the age group of 45 to 64 years in 
developing countries, while in developed countries the prevalence is higher in individuals 
over 65 years (2). 
Increased levels of glucose are also a factor responsible for atherosclerosis. 
Atherosclerosis is not only very common in diabetics as they have earlier and more 
extensive lesions than non-diabetics. Atherosclerotic disease in diabetics is often 
widespread, premature and severe, leading to stroke, disturbed circulation in the legs and 
changes in vision. It is believed that sugar acts directly or by favouring the formation of fat 
in the body and its penetration into the arterial wall (21). 
Cardiovascular risk increases with raised glucose values. Furthermore, abnormal glucose 
regulation tends to occur together with other known cardiovascular risk factors such as 
central obesity, elevated blood pressure, low high density lipoprotein (HDL) cholesterol 
and high triglyceride levels (10). 
1.3.7 Hyperlipidaemia 
The lipoprotein profile includes: (i) low density lipoprotein (LDL) cholesterol, also called 
“bad” cholesterol); (ii) HDL, also called “good” cholesterol; and (iii) very low density 
lipoprotein cholesterol.  
LDL cholesterol is deposited in the walls of arteries and causes atherosclerosis. In 
general, low LDL cholesterol levels are better for vascular health. HDL cholesterol 
protects against vascular disease by removing the LDL cholesterol out of the wall of 
arteries. 
Excess calories are converted into triglycerides and stored into fat cells throughout the 
body. High triglycerides also increase the risk of atherosclerotic CVD (10). 
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1.3.8 Oral contraceptives  
Oral contraceptives increase the risk of venous thrombosis, stroke and myocardial 
infarction. Although controversial, it has been accepted that the use of oral contraceptives 
is really another factor that increases the risk of atherosclerosis (21). 
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1.4  TRACE ELEMENTS 
Most of the naturally occurring elements are present in very low concentrations in the 
human body, and they commonly known as “trace elements”. Most of them are metals, 
but a few are non-metals (e.g., Se) or metalloids (e.g., As). 
Some trace elements (e.g., Cu, Zn, Se) are essential to the normal metabolic function, 
however they can become toxic at high levels of exposure. Others, such as Pb or Cd, only 
exert toxic effects in the human body, even at very low levels of exposure. In the 
toxicological literature/language, these particularly “toxic” elements are commonly referred 
as “heavy metals" (22). 
An indication of the importance of “heavy metals” in the context of particularly toxic 
substances is their place in the ranking of the U.S. Agency for Toxic Substances and 
Disease Registry (ATSDR), which lists the different substances according to their intrinsic 
of toxicity. The first, second, third and sixth in this list are Pb, Hg, As and Cd, respectively. 
Apart from not having any known metabolic function, when toxic trace elements are 
present in the body they can disrupt normal cellular processes, leading to toxicity in a 
number of organs. They are relatively poorly absorbed into the body, but once absorbed 
they are slowly excreted and can accumulate, causing organ damage. Consequently, 
toxic trace elements toxicity is largely due to their accumulation in tissues. Their 
distribution in the body depends on its binding capacity to carrier molecules in the 
circulation. Metallothioneins (Mt) are small proteins rich in cysteine residues that display 
unique metal-binding properties and play a major role in the distribution and storage of 
metals in the body (23). 
Disruption of metal ion homeostasis may lead to oxidative stress, a state where increased 
formation of reactive oxygen species (ROS) overwhelms body antioxidant protection and 
consequently induces DNA damage, lipid peroxidation, protein modification and other 
biochemical effects, all in the origin of numerous diseases, involving cancer, CVD, 
diabetes, atherosclerosis, neurological disorders (Alzheimer’s disease, Parkinson’s 
disease), chronic inflammation and others (24). 
On a laboratory perspective (particularly an analytical perspective), the intrinsic stability of 
metals facilitates their detection and quantification in biological materials, although the 
clinical significance of the values obtained is not always very clear. 
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1.4.1 Cadmium  
Cadmium is a "modern", very toxic metal. It occurs in the earth’s crust at a concentration 
of 0.1-0.5 ppm and is commonly associated with Zn, Pb and Cu ores. It is also a natural 
constituent of seawater, with average levels between 5 and 110 ng/L. Natural emissions 
of Cd to the environment can result from volcanic eruptions, forest fires, generation of sea 
salt aerosols and other natural phenomena (25). 
Cd main use is in plating and galvanizing due to its properties of corrosion resistance. It is 
also used in pigments for paints and plastics and as a cathode material for Ni-Cd 
batteries. Cd is a by-product of the mining and smelting of Pb and Zn, which are important 
sources of environmental pollution (26). 
Cd from polluted soil and water can accumulate in plants and organisms, thus entering the 
food chain. Smoking greatly increases exposure to Cd, as tobacco leaves naturally 
accumulate high amounts of Cd. It has been estimated that tobacco smokers are exposed 
to 1.7 μg Cd per cigarette, and about 10% of this is inhaled when smoked (25). 
With chronic exposure to Cd, approximately 50% of the accumulated dose is stored in the 
kidneys (27). After absorption, Cd is taken up by the hepatocytes, and then from the liver 
it circulates in the blood bound to Mt. At the kidney, the small molecular size of the Cd-Mt 
complex allows its easy filtration in the glomerular membrane and reabsorption by 
proximal tubular cells. Mt are then catabolised, releasing Cd ions in the tubular cells 
cytoplasm where they induce the synthesis of new Mt molecules (28). It then remains in 
the tubular cells and makes up for the major part of the Cd body burden. A number of 
studies have shown that this accumulation of Cd in kidneys causes tubular dysfunction 
and end-stage renal disease (29).  
Cd is toxic to tubular cells and glomeruli, markedly impairing renal function, these lesions 
consisting in initial tubular cell necrosis and degeneration, progressing to an interstitial 
inflammation and fibrosis (26).  
Chronic exposure to Cd has been associated with CVD. Increasing evidence supports that 
Cd may play a role in the development of a number of traditional CVD risk factors, 
including hypertension and chronic kidney disease, which could mediate in part the 
cardiovascular effects of Cd (30). 
Also, experimental evidence suggests that Cd could directly induce atherosclerosis 
initiation and progression. Several mechanisms have been suggested to explain the role 
of Cd in promoting atherosclerosis.  
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First, Cd indirectly increases ROS production and interferes with antioxidant defence by 
binding to Mt (31). 
Second, Cd reduces endothelial barrier function through disruption of endothelial cell–cell 
adhesions and by causing endothelial cell death, with subsequent attraction and activation 
of macrophages. Furthermore, due to Cd-caused necrotic death of endothelial cells and 
other cell types in the vessel wall, cellular remnants are released. All these phenomena 
cause cellular stress, resulting in the secretion of cytokines. A vicious circle of damage, 
stress and inflammation is then initiated (32).  
Third, Cd may partly contribute to atherosclerosis formation through vasopressor 
mechanisms such as direct vasoconstrictor action, inhibition of vasodilator substances 
(such as nitric oxide), or activation of the sympathetic nervous system (31). 
Other phenomena that have been observed in response to Cd exposure and initiate and 
promote atherosclerosis are hypertension, by salt retention and volume overload in the 
kidney (31). In rats it has been proven that Cd induces hypertension, but human studies 
have only yielded unconvincing and conflicting results (33). 
However, most existing studies on this topic are simply based on the analysis of body 
fluids such as blood and urine, since they can be easily obtained (34-37).  
1.4.2 Copper 
Cu is widely distributed in nature and is an essential trace element. Cu deficiency is 
characterized by hypochromic microcytic anemia resulting from a defective synthesis of 
hemoglobin. Antioxidant enzymes such as catalase, peroxidase, cytochrome oxidase and 
others also require Cu. Cu sulfate is used medically as an emetic. It has also been used 
as an anthelmintic for its intense and caustic action. Cu sulfate mixed with lime has been 
used as a fungicide (26).  
Approximately 55% to 75% of an oral dose of Cu is absorbed from the gastrointestinal 
tract, primarily in the duodenum. Intestinal Cu absorption can be reduced by zinc, iron, 
molybdate and fructose. The cellular transport and metabolism of Cu comprises a series 
of Cu-binding proteins and small peptides, such as albumin, ceruloplasmin (a sensitive 
marker of Cu levels in the body), glutathione, Mt and cytosolic Cu chaperons, which work 
in conjunction with Cu-ATPases to maintain Cu homeostasis. Cu levels are maintained 
mainly through control of biliary excretion, although Cu binding to hepatic Mt may act as a 
form of Cu storage. In mammals, little Cu is excreted into the urine, and the bile is the 
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major route of excretion. Bile secretion, enterohepatic recirculation and intestinal 
absorption all help to control Cu status (26). 
Cu is an essential component of several important enzymes, including type A oxidases 
and type B monoamine oxidase. Cytochrome c-oxidase is probably one of the most 
important because it catalyses a key reaction in energy metabolism, and inherited 
mutational defects can result in severe pathology in humans (26). 
Because Cu is a transition metal, it is capable of assuming different oxidation (or valence) 
states, and it is an active participant in redox reactions. 
One of the most accepted explanations for Cu-induced cellular toxicity comes from the 
assumption that Cu ions are prone to participate in the formation of ROS. Cupric and 
cuprous ions can act in redox reactions. The cupric ion (Cu2+), in the presence of 
biological reductants such as ascorbic acid or glutathione (GSH), can be reduced to the 
cuprous (Cu+) form, which is capable of catalyzing the formation of the highly reactive 
hydroxyl radicals (•OH) through the decomposition of hydrogen peroxide (H2O2) via the 
Fenton’s reaction:  
 
Figure 2  Fenton reaction. 
The hydroxyl radical is extremely reactive and can further react with practically any 
biological molecules (38).  
A consequence of the generation of hydroxyl radicals is lipid peroxidation. Oxidation of 
LDL has several consequences, including the promotion of atherogenesis by increasing 
the transformation of macrophages into foam cells and by developing vasoconstrictor and 
pro-thrombotic properties. While the in vivo relevance of the initiation of LDL oxidation by 
Cu ions is still unclear, in vitro studies have clearly demonstrated the oxidation of LDL 
induced by Cu. In vitro studies of LDL oxidation are performed by incubating the reaction 
system with Cu ions. The samples possessing atherosclerotic lesions contained either Cu 
or Fe ions capable of catalysing the formation of free radicals. In addition to the studies on 
the oxidation of LDL, it is also known that HDL is susceptible to oxidation (38). 
If Cu contributes to atherosclerosis or is simply a marker for other processes is a question 
that has yet to be solved, because the implications for prevention and treatment are very 
significant (39). 
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The kidneys accumulate Cu. Although primarily bound to Mt, when available, free Cu may 
participate in oxidation reactions (Figure 2), in a manner analogous to that of Fe. Thus, 
ROS are probably also responsible for the nephrotoxic effects of Cu (33).  
One of the largest population-based studies on the influence of Cu in CVD, the NHANES 
II Mortality Study, that gathered results of previous prospective studies, has shown a 
strong association between the serum Cu concentration and the rate of mortality from 
heart disease coronary. Generally, an increase in the risk was observed when the 
concentration of Cu in the serum was increased. In a Dutch case control study of 10,532 
people aged > 65 years, 62 subjects who died from CVD during the 6-9 years of follow-up 
were compared with 124 controls subjects (40). The relative risk of CVD among 
individuals with serum Cu concentration > 1.43 mg/L was 3.5 (CI 95%: 1.4-8.7), compared 
with subjects who had a serum Cu concentration in the interval 1.05 to 1.43 mg/L. 
1.4.3 Lead 
Lead occurs naturally in low concentrations in the earth's crust. The widespread 
occurrence of Pb in the environment is largely the result of anthropogenic activities. Pb 
has found wide use in pipes and plumbing, pigments and paints, gasoline additives, 
building materials and lead-acid batteries. The use of Pb in pipes, paints and gasoline 
additives resulted in substantial release of this metal into the environment and human 
exposure. More recently several measures to counter this were implemented. Because of 
its well-known toxicity to most living beings and because it was not demonstrated any 
biological need of Pb for life, the main discussion has been the determination of the dose 
from which it becomes toxic (26). 
More than 90% of Pb in blood is found in red blood cells (26). It is shown that 
gastrointestinal absorption, the main route of Pb entry into the body, varies widely, 
depending on the chemical environment on the gastrointestinal lumen, age and Fe stores 
(nutritional status) of the subject. Certain components of the diet may act by increasing 
the solubility of Pb, such as ascorbic acid, amino acids, vitamin D, proteins, fats and 
lactose, thus increasing its absorption. No feedback mechanism exists limiting the 
absorption of Pb. The amount absorbed is excreted primarily in the urine. Feces contain 
predominantly the Pb that was not absorbed. Being a calcium-like element, Pb usually 
follows the movement of Ca in the body and can be affected by the physiological 
regulators of Ca metabolism. Because bone storages more than 90% of the total body 
burden, increased bone turnover, either by physiological (e.g., pregnancy or lactation) or 
pathologic (e.g., osteoporosis) causes leads to the release of Pb from bone. Pb can be 
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remobilized from bone by competing with Ca for transport and for binding sites and it is 
released, along with Ca, when bone is resorbed. The mechanisms by which both 
elements enter and leave the bone are similar and, through these mechanisms, bone Pb 
equilibrates with blood Pb (23). 
The toxic effects of Pb can range from subtle biochemical effects to manifest clinical 
effects. Children are particularly sensitive to the toxic effects of Pb and the most critical 
effects are observed in the nervous system. For adults with excessive occupational 
exposure or even accidental exposure, the main concerns are peripheral neuropathy, 
chronic nephropathy and hypertension. Pb can directly affect blood pressure by changing 
the sensitivity of vascular smooth muscles to vasoactive stimuli or indirectly altering the 
neuroendocrine function of smooth muscle cells (26). 
The most important manifestation of Pb toxicity on the cardiovascular system is 
hypertension. This is likely caused by altered calcium-activated changes in contractility of 
vascular smooth muscle cell secondary to decreased Na+K+-ATPase activity and 
stimulation of the Na+-Ca2+ exchange pump. Pb may also effect vessels by altering 
neuroendocrine input or sensitivity to such stimuli or by increasing ROS that enhance 
nitric oxide inactivation (33). 
Population-based studies on the cardiovascular effects of Pb have focused mainly on the 
association with hypertension, an important risk factor for morbidity and mortality from 
CVD (41). The relationship between the blood Pb level and blood pressure has been 
described as statistically significant (42). The hypertension induced by high doses of Pb 
can be partly explained by the nephrotoxic action of this metal (43). In individuals exposed 
to low concentrations of Pb, renal function is responsible for a persistent increase in blood 
pressure, with an inverse association between glomerular filtration rate (GFR) and the 
concentration of Pb in blood, which was observed in people with blood levels as low as 10 
µg/dL (44) or even 5 µg/dL (45). It was also noticed that much other cardiovascular 
conditions, including CHD, stroke and peripheral artery disease were associated with 
exposure to Pb, but the exact role of Pb in CVD is not yet fully defined (46). 
In animal experimental studies it has been shown that Pb exposure promotes 
atherosclerosis. Depending on the degree and duration of the exposure, cardiac and 
vascular complications may be potentially fatal. There are also indications that chronic 
exposure to Pb can affect lipid metabolism (47). Current evidence on oxidative stress 
induced by Pb has been mainly based on in vitro experiments (48) or in animal studies 
(49). Chronic exposure has also been associated with atherosclerosis and increased 
cardiovascular mortality in humans (50). Several epidemiological studies among workers 
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with high occupational exposure have reported an association between Pb exposure and 
markers of oxidative stress (51). Epidemiological studies have reported that low-level Pb 
exposure has an association with several diseases such as hypertension and peripheral 
arterial disease (52, 53). 
1.4.4 Selenium 
The trace element Se is a non-metallic essential nutrient of fundamental importance to 
human biology. The biological role of Se in mammals, including man, is mainly attributed 
to the presence of selenocysteine at each of the four catalytic sites of the enzyme 
glutathione peroxidase (GPx). This enzyme uses glutathione to reduce peroxides in the 
cell and, this way, protects the lipid membranes and possibly proteins and nucleic acids 
from damage caused by free radicals and other oxidative agents. The need for Se is 
related to the degree of oxidative activity and the supply of nutrients such as Zn, Cu, Mn, 
Fe and vitamin E (26). 
The most extensively documented deficiency of Se in humans is Keshan disease, an 
endemic cardiomyopathy first discovered in Keshan County, People's Republic of China in 
1935. The disease is clinically characterized by varying degrees of cardiomegaly and 
cardiac decompensation. The histopathologic exam of the myocardium shows 
degeneration and necrosis of myocardial fibers and their replacement by fibrosis and 
areas of healing. 
Se deficiency is also one of the factors that influence the risk of hypertension and CVD. 
Furthermore, myocardial ischemia can also be worsened in case of Se deficiency (54). 
Experimental studies suggest that Se may reduce CVD risk via several mechanisms 
(Table 2). For example, antioxidant defences may reduce vascular and tissue injury 
resulting from formation of ROS due to shear stress, hypoxia, hypertension, 
hyperlipidemia or diabetes. Systems related to Se may also decrease the oxidation of 
lipids and protect the vascular endothelium from damage due to oxidized LDL particles. In 
animal studies, Se consumption has shown to increase cardiomyocyte GPx activity, to 
improve cardiac recovery from ischemia-reperfusion and to reduce the size of myocardial 
infarction (55). 
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Table 2  Experimentally-observed effects of selenium that may reduce CVD risk. (55) 
Systemic effects Direct cardiovascular effects 
Antioxidant defence against free radicals and 
reactive oxygen species 
Increased myocardial antioxidant glutathione 
peroxidase activity 
Decreased lipid peroxidation Improved cardiac recovery from ischemia-
reperfusion injury 
Protection against vascular damage from 
oxidized LDL particles 
Limitation of ischemia-induced and diabetes-
induced ultrastructural damage 
Antithrombotic effects from decreased 
plasma thromboxane A2 
Reduction in myocardial infarct size 
 Restoration of altered myocyte ion currents 
 Reduced incidence of ischemia-induced 
ventricular arrhythmias 
 
1.4.5 Zinc 
Zn is an essential trace element that is vital in maintaining normal physiology and cellular 
functions. Normal Zn levels in plasma are in the range of 70 to 120 mg/dL. Low levels of 
Zn (“deficiency”) are usually defined as Zn plasma levels lower than 60 mg/dL (56). 
The absorption of Zn from the gastrointestinal tract is homeostatically regulated. About 20-
30% of ingested Zn is absorbed into systemic blood circulation. Zn uptake from the 
intestinal lumen involves passive diffusion and a carrier-mediated process through specific 
Zn transporters, such as ZnT-1. Intestinal absorption of Zn can be reduced by dietary 
fiber, phytates, Ca and phosphorus, while amino acids, picolinic acid and prostaglandin 
E2 can enhance Zn absorption. Once absorbed, Zn is widely distributed throughout the 
body. The total content of Zn in the human body is in the range of 1.5-3 g. Most of this is 
found in muscle (60%), bone (30%), skin/hair (8%), liver (5%) and pancreas (3%). The 
highest concentrations of Zn are found in prostate, pancreas, liver and kidney. In plasma, 
Zn is mostly bound to albumin (60-80%), which represents the metabolically active pool of 
the element. The remainder is bound to α2-macroglobulin and transferrin. Zn is excreted 
both by urine and feces. The concentration of Zn in plasma is not a sensitive indicator of 
Zn status and does not reflect Zn levels in the tissues and its effects at the various target 
sites. Zn ions are involved as inter- and intracellular messengers and the homeostasis of 
Zn has to be tightly controlled (26). Zn is an effective inducer of Mt synthesis and, when 
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Mt become saturated in intestinal cells, Zn absorption is decreased. Mt are also an 
important intracellular Zn storage (26). 
Zn is found in more than 200 metalloenzymes, including acid phosphatase, alkaline 
phosphatase, alcohol dehydrogenase, carbonic anhydrase, superoxide dismutase and 
DNA and RNA polymerases. Zn contributes to gene expression and chelates with either 
cysteine or histidine in a tetrahedral configuration, forming looped structures know as Zn 
fingers, which bind to specific DNA regions. Other functions of Zn include membrane 
stabilization, vitamin A metabolism and the development and maintenance of the nervous 
system. Zn and Cu concentration generally have an inverse relationship in the serum, with 
elevated Zn concentrations resulting in decreased Cu concentrations (33).  
It is important to note that, although Zn ions per se are redox inert, they have profound 
effects on redox state and, conversely, redox state has a profound effect on Zn 
metabolism. Increased oxidative stress can release Zn from its binding sites, where it 
performs coordination function, as reported in a number of proteins (Fig. 3). Zn ions 
released from proteins may potentially act on signal transduction pathways, modify 
mitochondrial metabolism, and can affect the redox status of the cell. Zn at various 
concentrations can increase the cell’s antioxidant capacity or the release of toxic ROS 
(56). 
 
Figure 3 Chemical background for the flexibility of zinc ion in changing the redox environment 
(redox zinc switch). Zinc is coordinated in a reduced sulphur-containing protein domain and is 
released under oxidation. 
 
Numerous studies have explored the association of Zn with cardiomyopathies, 
arrhythmias and coronary diseases. Several investigators have shown decreased blood 
Zn levels in patients with ischemia/myocardial infarction, congestive heart failure, 
conduction abnormalities and heart transplant, resulting in poor outcomes (56). 
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The 'response to injury' hypothesis of atherosclerosis by Ross and Glomset (60) states 
that atherosclerosis begins with endothelial cell injury. It is now known that endothelial 
cells undergo apoptosis, possibly as a result of increased oxidative stress from oxidized 
LDL. Evidence suggests that Zn may be protective by maintaining the integrity of 
endothelial cells and thus reducing vessel susceptibility to atherosclerosis. Therefore, 
deficiency of Zn may corollary promote endothelial cell injury. A mediator of inflammatory 
responses in many cells is nuclear factor-kB (NF-kB), a transcription factor that regulates 
the gene expression associated with apoptosis and inflammation. The NF-kB binding to 
DNA is dependent on Zn and, consequently, the NF-kB transcriptional activity is regulated 
by Zn. In endothelial cells the Zn ionophore pyrithione inhibits the regulatory activity of NF-
kB, thereby inhibiting the inflammatory process responsible for the atherosclerotic process 
(56). 
 
Figure 4  Role of zinc in cardiovascular diseases. (56) 
Zn has not only an influence in the atherosclerotic process but also in other CVD like 
arrhythmias and myocardial infarction. In addition, Zn is involved in insulin signalling and 
the pathogenesis of diabetes, further indicating the potential role in diabetic 
cardiomyopathy. Zn supplementation also protects cardiomyocytes from acute redox 
stress and prevents inflammatory processes that are triggered during myocardial damage. 
Zn is also a wound-healing agent, and it is believe that it may support survival of cardiac 
stem cells that are essential components of cardiac healing. 
Some studies seem to corroborate the hypothesis that Zn may have an anti-
atherosclerotic role in both animals (57-59) and humans (60).  
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1.5  TRACE ELEMENT ANALYSIS 
As previously discussed, there is considerable evidence supporting the hypothesis that 
atherosclerosis involves chronic inflammation and oxidative stress, although the origin of 
oxidation is still not fully established. Various substances, including transition metal ions 
have been suggested as sources of oxidizing species in atherosclerotic lesions (5). Heavy 
metals ions are shown to be present at high levels in some animal models and also in 
human atherosclerotic plaques, which are in agreement with the hypothesis that metal 
ions contribute to the formation of plaque as well as for their destabilization (8, 61, 62). 
Many chemical elements occur in biological matrices at so low levels that they could not 
be detected at the beginning of the development of instrumental analysis (63). However, 
the extraordinary development of analytical techniques observed in last decades made 
possible a reliable quantification of these chemical species (“trace elements”), and 
contributed to the current understanding of the importance of these elements in human 
health and disease. 
One of the first important contributions to metal analysis in clinical chemistry was the 
introduction of the flame photometer, based on atomic emission spectrometry, which 
significantly improved Na and K determination (64). Later, the development of atomic 
absorption spectrometry (AAS) with flame atomization allowed faster determinations of 
several important metals (e.g., Ca, Mg, Fe, Cu, Zn), with great accuracy and precision, in 
small sample volumes. However, the range of analyzable metals was low due to its poor 
sensitivity (high detection limits). This limitation was overtaken in the 1970s with the 
introduction of the graphite furnace as atomization system, which greatly improves the 
efficiency of the atomization process (65). The development of atomic absorption 
spectrophotometry with graphite furnace (or electrothermal) atomization allowed to 
decrease by about 10 to 100 times the limits of detection for most metallic elements, 
making possible its quantification at the parts per billion (ppb) level (66). 
In practice, all spectroscopic elemental techniques, with different requirements regarding 
sample preparation and with an applicability dependent on the sensitivity and selectivity 
needed, can be used for the determination of trace elements in biological samples. 
Highlight for AAS, in its different atomization modes (flame atomization, electrothermal 
atomization and hydride generation), inductively coupled plasma-atomic emission 
spectrophotometry (ICP-AES), X-ray fluorescence and inductively coupled plasma-mass 
spectrometry (ICP-MS) (67). 
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In particular, ICP-MS is currently the “golden standard” for trace element analysis. The 
potential of ICP-MS in the determination of trace elements in various fluids (whole blood, 
plasma, serum, urine) and biological tissues is extensively illustrated in the literature (68). 
The combination of excellent metrological characteristics (very low limits of detection, 
typically in the order of 10-4-10-5 g/L, wide dynamic range, of nine orders of magnitude, 
and high precision) with very rapid multi-elemental analysis capability is the basis of the 
high potential of this analytical technique. This last feature (the ability to fast multi-
elemental analysis), in particular, makes ICP-MS a very important tool in the evaluation of 
the interactions and reciprocal effects of trace elements in the human body (67). 
A mass spectrometer comprises three main components: (i) an ion source (the plasma, in 
ICP-MS), which converts sample components in ions (mainly mono-elemental and 
positive, monovalent) in the gas phase; (ii) one (or more) mass analyzer, which separates 
the ions (ionized analytes) based on their mass-to-charge ratio (m/z); and (iii) a detector 
that counts the number of ions of each m/z value, producing a mass spectrum. 
The use of a high temperature plasma (6000-10000 ºC) as ion source for elemental mass 
spectrometry has been exploited over the last decades of the twentieth century, and the 
more successful combination was ICP-MS. After its commercial introduction in the early 
1980s (69), ICP-MS has become the leading technique for trace element analysis, 
allowing the fast determination of more than 70% of the elements of the periodic table. 
This stems from the fact that, due to the high temperature of the plasma, ionization and 
subsequent atomization is highly effective, i.e., a complete fragmentation of molecules in 
its constituent atoms and subsequent ionization occurs in a very large extent (70). 
 
Figure 5  Diagram of ICP-MS instruments (71). 
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One of the major problems in the analysis of biological fluids and tissues is the possible 
contamination of the samples at all stages of the analytical procedure (from sampling and 
preservation to sample pre-treatment and final instrumental analysis). It is well known that 
even slight hemolysis can increase the concentration of Fe, Cu, Zn, Pb, Rb, Mn and Mg in 
serum from several tens to several hundred percent. With the use of needles for sampling, 
the blood may be contaminated with Al, Cr, Ni and Zn. Glassware is another source of 
contamination, and is preferable to use plastic materials. The use of anticoagulants itself 
(heparin, EDTA) can contaminate the samples at the stage of sampling (67). 
The complex matrix of biological samples in most cases requires a step of sample 
preparation. Depending on the circumstances, sample preparation can range from a 
simple dilution of the sample to a thermal mineralization or an acid digestion in a 
microwave oven (67). 
The ideal process for solubilization of samples should be able to solubilize the sample 
completely, leaving no residue, should be reasonably fast and reagents used should not 
interfere with the subsequent determination or should be easily removable. It must also be 
taken into account that the reagents used should be available in high purity grade (to not 
contaminate the sample), and losses of analyte(s) must be insignificant. Together with 
these criteria, it must be taken into account that the reactants/reaction products should not 
attack the containers where solubilisation procedure is carried-out, and this should be a 
safe procedure. 
There are essentially two methods of solubilisation of samples: "dry ashing" (incineration, 
ashing; dry mineralization) and "wet ashing" (digestion; wet mineralization). The first is the 
classical method used to mineralize large amounts of samples with high organic content 
(e.g. biological samples, solid waste, sediments). The samples are heated at elevated 
temperatures (in a furnace) to destroy organic matter. The ashes are then treated as if 
they were a simple inorganic sample. This method has several limitations, such as the 
possibility of losing some of the more volatile elements, some ashes can be difficult to 
solubilize completely and there is a great potential for sample contamination. In the 
second case (wet digestion) the solubilisation is performed by using concentrated strong 
acids (e.g., HClO4, HNO3, HCl, H3PO4, H2SO4, HF) and/or other reagents such as 
H2O2, which lead to the decomposition of organic matter. This procedure can be done in 
two different ways: a) In open vessels – by simply bringing the mixture [acid(s) + sample] 
to boiling in a beaker covered with a watch glass; or b) in closed vessels – in a microwave 
oven, where microwave radiation provides the energy to heat the mixture. Although it can 
only be used for small sample masses (up to 1 g), the last one is a very efficient (because 
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it occurs at high pressures/temperatures) and safe solubilization process (it minimizes 
losses and contamination). 
The efficiency of wet (acid) digestion in a microwave oven depends on the nature of the 
sample, the adjustment of heating time, pressure and temperature, the mass of the 
sample and the type of acids used. Among these parameters, the choice of acid(s) is very 
important. Several concentrated acids such as nitric acid, hydrochloric acid, sulfuric acid 
or a mixture of these acids have been widely used to solubilize samples (68). The 
microwave heating is very efficient as heat is developed within the mixtures [sample + 
reagent (s)] and is not "driven" through the vessel walls as it happens when the sample is 
put into a vessel over an electric plate. Microwave heating also produces a very uniform 
heating. 
The acid digestion in closed vessels in a microwave oven has become the most important 
procedure for organic samples solubilization. As already highlighted, this procedure 
minimizes the amount of reagents required and, as a result, a reduced possibility of 
contamination (and the “sample blank” value). There is also a significant decrease in time 
spent on this task – the decomposition of the samples occurs at higher temperatures, 
which greatly increases the reaction rate. Importantly, the use of closed vessels makes it 
possible to avoid uncontrollable losses of trace elements, which inevitably occur when 
solubilisation is made in open vessels. This is a very important issue, especially when 
determining trace elements that form hydrides and/or volatile halides, such as As, B, Cr, 
Hg, Sb, Sn and Se (67). 
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2  OBJECTIVES  
The link between trace element imbalances and CVD is not fully understood. Most of the 
existing studies on this subject are simply based on the analysis of body fluids (blood, 
serum, plasma, urine), since they can be easily obtained. 
From a theoretical point of view, a potentially more conclusive approach could be the 
direct study of trace elements changes in the target organs and tissues, and this was the 
rational for the study performed. 
The study focused on five trace elements: Zn, Cu, Se – three elements with a well-
recognized “essentiality”, needed for very important physiological functions; Cd and Pb – 
two important "toxic" trace elements, whose role in atherosclerosis and CVD is long 
suspected. 
Basically, we aimed to directly look, in the tissues themselves, for evidences of significant 
changes in trace elements levels that could be related to CVD.  
For a better understanding of these changes, the age-related changes in “normal” (non-
diseased individuals), the gender-related differences and the effect of smoking habits 
were also assessed. 
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3.1  LABORATORY WARE 
Glass and metal materials were avoided in order to reduce the risk of contamination. 
Whenever possible, polypropylene made labware (pipette tips, volumetric flasks, tubes, 
auto sampler cups, etc.) was used. 
All material was previously decontaminated with 10% (v/v) HNO3 before being thoroughly 
rinsed with ultrapure water. Ultrapure water (resistivity > 18.2 MΩ.cm at 25 °C) was 
obtained by de-ionization with mixed bed ion-exchange resins and further purification in 
an Arium® pro B water purification system (Sartorius, Germany). 
3.2  SUBJECTS 
This study was conducted in kidney and aorta samples obtained from individuals (n=56) 
submitted to medico-legal autopsy exam at Instituto Nacional de Medicina Legal e 
Ciências Forenses, I.P. – Delegação do Norte (INMLCF) during the period of October 
2013 to February 2014. 
Samples were collected during the medico-legal autopsy by the cooperating forensic 
pathologists. Only individuals with a post-mortem interval (i.e., the time that has elapsed 
since the person has died) lower than 72 hours were considered for the study. 
In order to fulfil all current legal regulations regarding human tissue collection for scientific 
research purposes, it was assured that the individual’s name was not registered in the 
Portuguese “Registo Nacional de Não Dadores” (RENNDA) database. 
Two groups of individuals were studied: 
Group A – “Healthy” individuals (n=19). Clinicopathological criteria were used for case 
selection: absence of a cardiovascular disease history and atheromatous plaques causing 
less than 50% of luminal obstruction.  
Group B – Individuals with evidence of “cardiovascular diseases” (n=23). Clinical condition 
was evaluated through the examination of medical files and a standard questionnaire to 
relatives. Cases of drowning, burns, severe sepsis or history of severe systemic disease 
were excluded from the study. 
Note: In total, samples from 54 individuals were collected. However, it was not possible to 
include all the individuals in one of the above defined groups because it was not always 
possible to assess the degree of lumen obstruction caused by atheromatous plaques. 
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3.3  SAMPLE COLLECTION 
Kidney tissue: renal cortex and renal medulla – For systematic reasons, the right 
kidney was always collected. Using a long-bladed knife, a longitudinal cut was made 
along the kidney, in order to expose the cortex and the medulla (Fig. 6). Then fragments 
of about 1 cm3 (~1 g) were collected from the cortical and medullar zones of the kidney. 
 
Figure 6 (a)  Schematic representation of kidney anatomy; (b) Nephron structure (72) 
 
Aorta tissue (with and without evidence of atherosclerotic plaques) – For systematic 
reasons, samples were always collected from the thoracic aorta. Using plastic knives, 
samples from aorta segments, both with and without evidence of atherosclerotic plaques, 
were collected (n=54).  
In all cases, after samples removal from the corpse, blood residues were thoroughly 
cleansed with ultrapure water. Samples were then stored into decontaminated 
polypropylene tubes. After transport to laboratory in refrigerated conditions, samples were 
stored frozen (-20 ºC).  
3.4  SAMPLE PREPARATION 
Before analysis, samples were washed several times with ultrapure water and placed in a 
dry oven, at 110 ºC, until constant weight (approximately 24 hours). Then, between 100 
and 500 mg of the dried samples were weighted into the Teflon microwave oven digestion 
vessels (previously decontaminated and washed with ultrapure water). 
(a) 
(b) 
33 
 
Samples were digested using 2.5 mL of concentrated (≥ 65%), high-purity HNO3 
(TraceSELECT®, Sigma-Aldrich, France) and 1.0 mL of concentrated (≥ 30%) high-purity 
H2O2 (TraceSELECT® Ultra, Sigma-Aldrich) in a MLS-1200 Mega microwave oven 
(Milestone, Italy) equipped with an HPR-1000/10 S rotor. The microwave oven program is 
shown in next Table. 
Table 3  Microwave oven program for samples acid digestion. 
Step Power (W) Time (min.) 
1 250 1 
2 0 2 
3 250 5 
4 400 5 
5 600 5 
 
After cooling, the vessels content was transferred into decontaminated polypropylene 
volumetric flasks and diluted to 50 mL with ultrapure water. The solutions were stored in 
decontaminated polypropylene tubes at 4 °C until analysis. 
3.5  SAMPLE ANALYSIS 
The analytical determination of Cd, Cu, Pb, Se and Zn was performed using a VG 
Elemental (Winsford, UK), PlasmaQuad 3 ICP-MS instrument, equipped with a Meinhard® 
type A pneumatic concentric nebulizer, a water-cooled quartz spray chamber with impact-
bead, a standard quartz torch and nickel sample and skimmer cones. Both the spray 
chamber and the ICP-MS interface system were cooled to 12 ºC by circulating water. High 
purity (99.9999%) argon (Gasin, Portugal) was used as nebulizer and plasma gas. For 
sample introduction, a Gilson (Villiers le Bel, France) model M312 peristaltic pump was 
used. A 2% (v/v) HNO3 solution was used for the washing of the sample introduction 
system. 
The elemental isotopes (m/z ratios) 55Mn, 65Cu, 66Zn, 111Cd and 208Pb (as analytical 
masses) and 45Sc, 89Y, 115In, 159Tb and 209Bi (as internal standards) were monitored. 
The limit of detection (LoD) and the limit of quantification (LoQ) were calculated as the 
concentration corresponding to 3 and 10 standard deviations of 10 repeated 
determinations of the blank signal, respectively. Expressed as μg/g in real samples 
(tissues), the LoQ achieved were: 0.59 (Cu); 1.01 (Zn); 0.735 (Se); 0.04 (Pb) and 0.11 
(Cd). 
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A 10 μg/L tuning solution was prepared by dilution of a commercial multi-element aqueous 
solution (AccuTrace™, ICP-MS 200.8-TUN-1; AccuStandards, New Haven, CT, USA). 
The ICP-MS instrument was daily tuned for maximum signal sensitivity and stability using 
115In as the target isotope. 
Internal standards (Sc, Y, In, Tb and Bi) solution was prepared by dilution of a commercial 
solution (AccuTrace™, ICP-MS 200.8-IS-1; AccuStandards). It was added to all the 
samples and standards solutions in order to obtain a 10 μg/L final concentration. 
ICP-MS calibrating solutions were prepared by dilution of a commercial multi-element 
aqueous solution (AccuTrace™, ICP-MS 200.8-CAL1R-1; Isostandards Material, Madrid, 
Spain). Calibration curves were obtained with six solutions of element concentrations 
within the 1-200 μg/L range. 
All the solutions were prepared with 2% (v/v) HNO3. 
3.6  ANALYTICAL QUALITY CONTROL 
Since kidney and aorta tissue are not available as certified reference materials (CRM) for 
trace element analysis, DOLT-4 (dogfish liver) and DORM-3 (fish Protein), CRM available 
from the National Research Council (Canada) and independent standard solutions were 
used to validate and ensure accuracy of the analytical procedure. CRM were subjected to 
the same sample pre-treatment and were analysed within the concentration range of the 
analytes in the sample. 
For contamination control during the microwave-assisted acid digestion procedure, a 
sample blank was performed in each digestion cycle (10 samples). 
All the samples, after adequate dilution, were analyzed in duplicate (two determinations in 
the same analytical run). For results with relative standard deviation ≥ 10% two additional 
determinations were performed. 
3.7  STATISTICAL ANALYSIS 
Data statistical analysis was performed using GraphPad Prism 5 for Windows (San Diego, 
California, USA) statistical software package, version 5.04. 
For each sample, element concentration (μg/g) was expressed as the mean±SD of the 
two replicate determinations.  
Descriptive statistical parameters (mean, median, standard deviation, minimum and 
maximum) were calculated for each element in each sample type (kidney cortex and 
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kidney medulla; aorta with and without evidence of atherosclerotic plaques; 
atherosclerotic plaques).  
For the statistics calculation, results that fell below the LoQ were assumed as the LoQ 
divided by the square root of 2, a commonly used procedure for data imputation in such 
cases (73). 
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4.1  KIDNEY 
4.1.1 Medulla 
a) All the samples  
 
Table 4  Concentration (µg/g) of elements in kidney medulla. 
 
Cu Zn Se Cd Pb 
N 57 57 53 57 57 
Mean 6.72 115.7 3.97 41.37 0.26 
SD 3.98 86.48 2.18 38.72 0.21 
Median 6.29 89.74 3.86 31.36 0.19 
Minimum 1.28 16.93 0.81 4.47 0.04 
Maximum 15.82 437.4 9.05 210.7 1.01 
 
b) Men vs Women  
In medulla, no significant difference was found between genders for Cd, Cu, Se and Zn 
(Tables 5 and 6). Most of the available literature is focused on the metal content of 
kidney cortex. Results for renal medulla are very scarce. Lower Zn and Se levels 
have been found in women blood serum (74), but apparently this is not reflected in 
the content of renal medulla tissue. 
Table 5  Concentration (µg/g) of elements in kidney medulla in men. 
Men Cu Zn Se Cd Pb 
N 35 35 34 32 35 
Mean 6.69 121.8 4.60 36.95 0.32 
SD 4.19 97.15 5.78 23.79 0.23 
Median 6.29 84.42 3.66 34.74 0.27 
Minimum 1.28 16.93 0.81 4.47 0.05 
Maximum 15.82 437.4 35.32 83.90 1.01 
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Table 6  Concentration (µg/g) of elements in kidney medulla in women. 
Women Cu Zn Se Cd Pb 
N 18 18 17 17 18 
Mean 7.02 109.3 4.80 24.72 0.16 
SD 3.82 68.30 2.88 14.10 0.10 
Median 6.56 106.8 4.03 26.53 0.14 
Minimum 1.47 21.31 1.55 5.57 0.04 
Maximum 13.97 301.0 11.90 54.96 0.46 
 
For Pb, a higher concentration was found in men (0.32±0.23 versus 0.16±0.10 in women; 
p≤0.01) (Figure 7).  
In general, men have higher blood Pb levels than women. Pb in blood is bound to 
hemoglobin, inside the erythrocytes. Therefore, since men have higher hematocrit values 
(and higher haemoglobin values), it is expected that higher Pb levels are also found in 
men (75). 
Our findings may also be due to a higher percentage of smokers in the men sub-group 
(35,5% vs 13,6% in the women sub-group), and smoking is an important source of human 
exposure to Pb (29). 
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Figure 7  Lead levels (g/g) in kidney medulla in men (n=35) and women (n=18), **p ≤0.01 
39 
 
c) Smokers vs Non-smokers 
Results for Cu, Zn, Se, Cd and Pb in the renal medulla tissue of smokers and non-
smokers are shown in next tables. 
Table 7  Concentration (µg/g) of elements in kidney medulla of smokers. 
Smokers Cu Zn Se Cd Pb 
N 13 13 11 13 13 
Mean 7.46 166.7 3.26 75.97 0.39 
SD 4.71 112.1 1.77 61.04 0.19 
Median 6.66 146.7 2.66 52.00 0.33 
Minimum 1.28 24.53 0.81 7.03 0.14 
Maximum 15.82 437.4 6.05 210.7 0.70 
 
Table 8  Concentration (µg/g) of elements in kidney medulla of non-smokers. 
Non-smokers Cu Zn Se Cd Pb 
N 28 28 28 28 28 
Mean 6.16 91.46 4.06 27.78 0.21 
SD 3.60 63.47 2.51 20.24 0.20 
Median 5.83 76.15 3.61 20.87 0.16 
Minimum 1.44 16.93 1.16 4.47 0.05 
Maximum 13.97 301.0 11.90 80.29 1.01 
 
Plants have evolved physiological mechanisms to gain access to essential elements from 
the soil. On the other hand, plants can accumulate toxic metals, which is an ability used 
by modern biotechnology to remove metals from contaminated soils. However, regarding 
Nicotiana tabacum farming for cigarette production, this ability of tobacco plant becomes a 
health problem. Toxic metals such as Cd, Pb, Hg and Ni are found in tobacco, and 
consequently in cigarette smoke (29). 
Recent data suggests that smoking interferes with the metal homeostasis of the human 
body and plays a crucial role in the pathogenesis of a number of diseases. It was 
demonstrated that metals present in cigarette smoke are essential in the process that led 
to the injury of the vascular endothelium (76). And as already pointed out, the dysfunction 
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and disruption of vascular endothelium is the primary event in the genesis of 
atherosclerosis (29). 
We found a significant difference between smokers and non-smokers regarding the 
kidney medulla levels of Cd, Zn (Figure 8) and Pb (Figure 9). 
The average content of Zn in cigarettes has been estimated in 24 µg/g and about 70% is 
transferred to the smoke. Studies regarding the relationship between plasma Zn 
concentration and smoking habits found no differences in Zn levels between smokers and 
non-smokers (74, 77). In our study, however, a significantly higher Zn content in the renal 
medulla of smokers (166.7±112.1 µg/g versus 91.46±63.47 µg/g in non-smokers; p≤0.01) 
was found (Figure 7). It seems that excretion by the kidney tends to increase to remove 
the excess of Zn inhaled via smoke. 
Smokers also showed significantly higher levels of Cd (75.97±61.04 µg/g vs 27.78±20.24 
µg/g in non-smokers) (Figure 8). This is in accordance with Scott et al. (78), who also 
found increased levels of Cd in smokers kidney tissue. 
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Figure 8  Cadmium and zinc levels (µg/g) in kidney medulla of smokers (n=13) and non-smokers 
(n=28); **p≤0.01, ***p≤0.001 
The Pb content of a cigarette has been estimated around 1.2 µg, and about 6% of this 
total amount is thought to pass over to mainstream smoke, which is further inhaled by 
smokers (29). Navas-Acien et al. (53) and Mortada et al. (79) reported higher Pb levels in 
smokers blood. In our study, Pb was significantly higher in the smokers’ renal medulla: 
0.39±0.19 µg/g versus 0.21±0.20 µg/g in non-smokers (Figure 9).  
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Figure 9  Lead levels (g/g) in kidney medulla of smokers (n=13) and non-smokers (n=28); 
*p≤0.05 
d) Differences by area of residence 
Because of the large inter-individual variability, different number of smokers and unequal 
distribution of subjects across the different geographical areas, it is not possible to draw 
significant conclusions about the influence of the area of residence in the trace element 
levels in kidney medulla. 
However, individuals from Gondomar showed lower Cu levels in kidney medulla (without 
reaching statistical significance) (Figure 10) and Zn (p≤0.05) (Figure 11). Individuals from 
Santo Tirso and Vila do Conde showed lower concentrations of Cd (Figure 11). 
42 
 
 
Figure 10  Average concentration (µg/g) of Cu, Se and Pb in renal medulla according to 
individuals’ area of residence. 
 
Figure 11  Average concentration (µg/g) of Zn and Cd in renal medulla according to individuals’ 
area of residence.  
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4.1.2 Cortex 
a) All the samples 
Table 9  Concentration (µg/g) of the elements in kidney cortex. 
 Cu Zn Se Cd Pb 
N 56 56 51 56 56 
Mean 7.52 166.1 4.83 72.57 0.34 
SD 4.10 100.2 2.54 45.43 0.39 
Median 7.61 144.9 4.84 67.97 0.26 
Minimum 1.68 31.54 1.47 0.03 0.02 
Maximum 16.63 409.5 12.30 198.5 2.56 
 
b) Men vs Women 
No significant difference was found between genders for any of the five analysed 
elements in kidney cortex (Tables 10 and 11).  
These results are in close agreement with those found in other studies where no 
significant gender-related differences were also found regarding Pb, Cd, Cu, Se and Zn 
levels in the kidney (80-82). 
Table 10  Concentration (µg/g) of elements in kidney cortex of men. 
Men Cu Zn Se Cd Pb 
N 33 33 29 33 32 
Mean 7.20 168.05 4.34 78.54 0.35 
SD 4.28 105.46 2.14 47.35 0.30 
Median 5.68 139.54 4.06 75.42 0.28 
Minimum 1.68 31.54 1.47 18.87 0.02 
Maximum 16.63 409.48 9.88 198.49 1.20 
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Table 11  Concentration (µg/L) of elements in kidney cortex of women. 
Women Cu Zn Se Cd Pb 
N 20 20 19 20 20 
Mean 8.25 171.7 5.69 68.92 0.25 
SD 3.87 94.88 2.99 42.97 0.16 
Median 8.79 154.0 4.90 60.83 0.25 
Minimum 2.34 48.97 1.68 0.03 0.04 
Maximum 12.90 403.0 12.30 179.5 0.63 
 
c) Smokers vs Non-smokers 
No significant differences were found between smokers and non-smokers regarding Cu, 
Zn, Se and Zn levels in kidney cortex (Tables 12 and 13).  
Studies on the concentration of Cu in serum (77, 83) showed higher levels of this element 
in smokers. Since free Cu2+ ions are potent catalysts in Fenton reaction (Figure 2), these 
observations might indicate and increased risk of oxidative stress. 
No clear evidence exists about the influence of smoking in Zn levels. Garcia et al. (80) 
didn’t found a significant difference in Zn levels between smokers and non-smokers, but 
Blanusa et al. (84) found higher levels in smokers.  
Table 12  Concentration (µg/g) of elements in kidney cortex of smokers. 
Smokers Cu Zn Se Cd Pb 
N 14 14 12 14 14 
Mean 8.31 210.0 4.28 110.1 0.43 
SD 4.65 103.9 1.87 37.74 0.40 
Median 9.39 195.1 4.72 110.6 0.280 
Minimum 1.98 66.59 1.87 48.09 0.02 
Maximum 16.63 409.5 8.09 179.5 1.20 
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Table 13  Concentration (µg/g) of elements in kidney cortex of non-smokers. 
Non Smokers Cu Zn Se Cd Pb 
N 29 29 26 29 29 
Mean 7.49 159.9 5.91 51.06 0.34 
SD 3.85 103.6 2.98 27.62 0.46 
Median 7.67 124.8 6.20 44.74 0.27 
Minimum 2.15 31.54 1.68 0.03 0.04 
Maximum 15.94 403.0 12.30 110.7 2.59 
 
Cd showed significant higher levels in smokers (110.1±37.74 µg/g versus 51.06±27.62 
µg/g in non-smokers) (Figure 12). This is in close agreement with other studies on the 
influence of smoking habits in the Cd content of kidney cortex (81, 82, 84). 
Smoking is assumed to be the main source of human exposure to Cd. Although the 
amounts of Cd varied, the average content of this element has been found between 0.5 
and 1.5 µg per cigarette (29). When the cigarette is smoked, Cd is transformed into CdO, 
which is then inhaled. It is estimated that approximately 10% of the Cd inhaled is 
deposited in the lungs, and 20-50% of this amount is transferred to the blood circulation. 
Cd not only increases in the circulation, but also accumulates in kidney, mainly in the 
kidney cortex, where Mt chelate and immobilize it. As already stressed, studies have 
shown that Cd accumulation in kidney causes tubular dysfunction and renal failure, but 
there is also some evidence that the amount of Cd released with the smoke is not enough 
to cause kidney failure (29). 
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Figure 12  Cadmium levels (g/g) in the kidney cortex of smokers (n=14) and non smokers (n=29); 
****p≤0.0001 
d) Differences by area of residence  
No significant differences were found between areas of residence. Individuals from 
Matosinhos showed higher levels of Zn and individuals from Gondomar showed lower 
levels of Cd (Figure 13), but the difference reached no statistical significance.   
 
Figure 13  Average concentration (µg/g) of Cu, Se and Pb in renal cortex according to individual’s 
area of residence. 
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Figure 14  Average concentration (µg/g) of Zn and Cd in cortex according to individual’s area of 
residence. 
4.1.3 Cortex vs Medulla 
Although we have found a tendency for higher levels of all the studied trace elements in 
the kidney cortex, the difference was statistically significant only for Zn (166.1±100.2 µg/g 
in renal cortex and 115.7±86.48 in renal medulla; p≤0.01) and Cd (72.57±45.43 µg/g in 
cortex and 41.37±38.72 µg/g in medulla; p≤0.0001) (Figure 15). 
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Figure 15  Cadmium and zinc levels (g/g) in kidney cortex (n=56) and medulla (n=57); **p ≤0.01, 
****p ≤0.0001 
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As previously mentioned, the renal filtration and reabsorption of Cd–Mt complexes occurs, 
respectively, at the glomerulus and proximal tubules, which are both nephron structures 
located in renal cortex (Figure 6). This may explain the higher levels of Cd found in kidney 
cortex. 
On the other hand, it seems that Cd-Mt and Zn-Mt complexes are handled by the same 
renal mechanism (85), which explains the concomitant Zn accumulation in the kidney 
cortex.  
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4.2  AORTA TISSUE 
4.2.1  Aorta tissue without plaque of atheroma 
a) All samples  
 
Table 14  Concentration (µg/g) of the elements in aorta tissue without plaque of atheroma 
 
Cu Zn Se Cd Pb 
N 52 52 45 52 52 
Mean 4.28 89.74 4.71 1.55 3.22 
SD 1.21 28.45 2.33 2.72 3.58 
Median 4.08 88.03 4.40 0.13 1.93 
Minimum 1.83 21.22 1.51 0.03 0.06 
Maximum 8.15 175.7 14.17 10.91 14.35 
 
In aorta tissue without plaque of atheroma Zn was the element present at higher levels 
and Cd at the lower. The whole results are summarized in Table 14.  
b) Men vs Women 
No differences were found between genders (Tables 15 and 16).  
Table 15  Concentration (µg/g) of the elements in aorta tissue without plaque of atheroma of men. 
Men Cu Zn Se Cd Pb 
N 28 28 23 28 28 
Mean 4.15 86.54 5.00 1.36 2.92 
SD 1.08 32.26 2.76 2.71 2.94 
Median 3.99 83.58 4.68 0.08 1.96 
Minimum 1.83 21.22 1.90 0.03 0.10 
Maximum 5.69 175.7 14.17 10.09 12.42 
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Table 16  Concentration (µg/g) of the elements in aorta tissue without plaque of atheroma of 
women 
Women Cu Zn Se Cd Pb 
N 19 19 17 19 19 
Mean 4.19 88.54 4.33 1.15 3.27 
SD 1.14 19.28 1.62 2.00 3.87 
Median 4.43 91.82 4.21 0.16 1.80 
Minimum 2.25 44.64 1.51 0.03 0.06 
Maximum 5.93 115.2 7.40 6.69 14.19 
 
c) Smokers vs Non-smokers 
No differences were also found between smokers and non-smokers (Tables 17 and 18). 
Table 17  Concentration (µg/g) of the elements in aorta tissue without plaque of atheroma of 
smokers. 
Smokers Cu Zn Se Cd Pb 
N 13 13 11 13 13 
Mean 4.36 85.37 5.29 2.02 2.40 
SD 0.96 20.79 3.28 3.20 2.13 
Median 4.01 86.64 4.53 0.17 2.09 
Minimum 3.20 43.11 2.30 0.04 0.11 
Maximum 5.93 116.51 14.17 10.09 7.70 
 
Table 18  Concentration (µg/g) of the elements in aorta tissue without plaque of atheroma of non-
smokers. 
Non-Smokers Cu Zn Se Cd Pb 
N 25 25 22 25 25 
Mean 4.02 86.43 4.62 1.48 3.41 
SD 1.14 26.18 1.94 2.34 3.75 
Median 3.87 83.92 4.26 0.09 1.80 
Minimum 2.04 21.22 1.51 0.03 0.06 
Maximum 6.26 131.89 9.91 7.84 14.19 
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4.2.2 Aorta tissue with plaque of atheroma 
a) All samples 
Table 19  Concentration (µg/g) of the elements in aorta with plaque of atheroma. 
 
Cu Zn Se Cd Pb 
N 41 41 36 40 41 
Mean 3.74 111.0 3.85 1.22 2.95 
SD 2.78 58.42 2.50 3.81 2.61 
Median 3.23 94.52 3.65 0.08 2.47 
Minimum 1.10 30.06 0.52 0.01 0.05 
Maximum 14.69 350.2 13.52 23.28 10.81 
 
b) Men vs Women 
No differences were found between genders (Tables 20 and 21). 
Table 20  Concentration (µg/g) of the elements in aorta with plaque of atheroma of men. 
Men Cu Zn Se Cd Pb 
N 22 22 18 22 22 
Mean 3.79 105.5 3.41 1.64 2.56 
SD 2.68 51.17 2.05 5.00 1.95 
Median 3.26 89.21 2.95 0.08 2.00 
Minimum 1.31 30.06 0.52 0.01 0.19 
Maximum 14.24 217.6 10.13 23.28 6.95 
 
Table 21  Concentration (µg/g) of the elements in aorta with plaque of atheroma of women. 
Women Cu Zn Se Cd Pb 
N 18 18 17 17 18 
Mean 3.67 116.78 3.75 0.67 3.00 
SD 3.05 68.58 1.77 1.43 2.75 
Median 2.93 98.78 3.77 0.08 2.67 
Minimum 1.10 39.67 1.60 0.01 0.05 
Maximum 14.69 350.23 7.19 5.23 9.45 
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c) Smokers vs non smokers 
Table 22  Concentration (µg/g) of the elements in aorta with plaque of atheroma of smokers. 
Smokers Cu Zn Se Cd Pb 
N 10 10 9 10 10 
Mean 3.47 78.44 3.93 0.91 1.84 
SD 1.03 32.25 1.62 1.63 1.69 
Median 3.49 70.09 3.77 0.16 1.29 
Minimum 1.75 39.67 1.81 0.01 0.09 
Maximum 5.09 147.2 7.19 5.23 5.83 
 
Table 23  Concentration (µg/g) of the elements in aorta with plaque of atheroma of non- smokers. 
Non-Smokers Cu Zn Se Cd Pb 
N 20 20 20 17 20 
Mean 3.36 126.4 3.33 0.47 3.51 
SD 2.94 66.60 1.56 1.29 2.67 
Median 2.50 106.8 3.65 0.07 3.06 
Minimum 1.10 40.88 0.52 0.01 0.10 
Maximum 14.69 350.2 7.10 23.28 9.45 
 
A significant difference was found for Zn levels in aorta with plaque. Smokers showed a 
lower Zn concentration: 78.44±32.25 µg/g vs 126.5±66.60 in non-smokers (p≤0.05) 
(Figure 16). 
The mechanism through which cigarette smoke reduces Zn levels is the aorta with plaque 
of atheroma is thought to be the result of an increased blood Cd concentration, which 
induces the expression of Mt. Mt complexes not only bind Cd but also Zn, and later this 
complexes accumulate in the renal cortex (29). 
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Figure 16  Zinc levels (g/g) in aorta tissue with plaque of atheroma of smokers (n=10) and 
non-smokers (n=20); *p≤0.05 
d) Differences by area of residence 
As also observed in renal medulla, individuals from Santo Tirso and Vila do Conde 
showed lower concentrations of Cd in aorta tissue (with and without plaque) (Figure 17). 
 
Figure 17  Average concentration (µg/g) of Cu, Cd, Pb and Se in aorta according to individuals’ 
area of residence. 
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Figure 18  Average concentration (µg/g) of Zn in aorta according to individuals’ area of residence. 
 
4.2.3 Aorta tissue with and without plaque of atheroma 
Significant differences were found between both aorta tissues (i.e., with and without 
plaque of atheroma) for Zn and Se. 
For Zn, significantly higher concentrations were found in aorta tissue with plaque of 
atheroma: 111.0±58.42 µg/g vs 89.74±28.45 µg/g in aorta without plaque (Figure 19). 
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Figure 19  Zinc levels (g/g) in aorta tissue without plaque of atheroma (n=52) and aorta tissue 
with plaque of atheroma (n= 41); *p≤0.05 
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Our results are in agreement with those obtained by Tohno et al. (86), who studied the 
human thoracic aorta and found a lack of correlation between Zn and some independent 
markers of protein oxidation (tyrosine nitration and thiol oxidation), suggesting that Zn is 
unlikely to protect against transition metals induced lipoprotein oxidation. Moreover, a 
highly significant correlation between Zn and Ca in all lesions was observed. It seems that 
high Zn levels may merely be an indicator of Ca accumulation and fibrosis.  
Regarding Se, we found a significantly higher concentration of this element in the aorta 
tissue without plaque of atheroma (4.71±2.33 µg/g) when compared with the aorta tissue 
with plaque of atheroma (3.85±2.50 µg/g) (Figure 20). 
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Figure 20  Selenium levels (g/g) in aorta tissue without plaque of atheroma (n=45) and in aorta 
tissue with plaque of atheroma (n=36); **p≤0.01 
The higher Se concentration in aorta without plaque seems to confirm that Se is a 
cardioprotector element (87). 
In a study by Lubos et al. (88), the plasma Se concentration of individuals with acute 
coronary syndrome was inversely associated with cardiovascular mortality, independently 
of classical risk factors. 
The exact mechanism through which low plasma Se levels act in CVD is not yet known. 
Some authors have pointed out that low Se concentrations in atherosclerosis may 
facilitate the formation of lipid hydroperoxides, which could attack vascular endothelium. 
Other authors have argued that Se modifies prostaglandin synthesis, improving 
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thromboxane levels in platelets and diminishing prostacyclin concentration in vascular 
endothelium. In these circumstances, Se, as an antioxidant agent, is closely related to 
prostaglandin metabolism, since it acts as a GPx cofactor. Another mechanism would be 
the protective action of Se against the toxicity of heavy metals (88). 
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4.3  AGE-RELATED CHANGES 
4.3.1 Kidney  
For Cd levels in renal cortex, an age-related increase up to 50 years old with a 
subsequent decrease was found (Figure 21). This behaviour has already been reported 
from previous studies (80). The decline in Cd levels after 50 years of age may be due to 
an age-related degeneration or Cd-induced damage of the kidney tissue. In medulla, no 
significant age-related changes in Cd levels were found. 
 
Figure 21  Relationship between Cd levels (µg/g) in kidney and age (years). 
For Cu, Zn, Pb and Se linear regression analysis of metal content versus age produced 
positive slopes, suggesting a tendency for an increase in the elements levels with age 
(Figures 22-25). For Zn, this is in disagreement with Garcia et al. (79), who reported no 
age-related changes in kidney tissue levels. This is also in disagreement with the same 
authors (79) for Pb, as they reported a decrease in kidney Pb levels with age. 
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Figure 22  Relationship between Cu levels (µg/g) in kidney and age (years). 
 
 
Figure 23  Relationship between Zn levels (µg/g) in kidney and age (years). 
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Figure 24  Relationship between Pb levels (µg/g) in kidney and age (years). 
 
  
Figure 25  Relationship between Se levels (µg/g) in kidney and age (years).  
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4.3.2 Aorta 
Except for Pb, which showed to increase with age (Figure 29), Cu, Zn, Cd and Se in aorta 
tissue without plaque of atheroma showed quite constant levels with the age increasing 
(Figures 26, 27, 28, 30).  
For aorta tissue with plaque of atheroma linear, Cu, Cd and Se showed a tendency for a 
decrease with age (Figure 26, 28 and 30), while Zn and Pb showed a tendency to 
increase (Figures 27 and 29). 
 
 
Figure 26  Relationship between Cu levels (µg/g) in aorta and age (years). 
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Figure 27  Relationship between Zn levels (µg/g) in aorta and age (years). 
 
 
Figure 28  Relationship between Cd levels (µg/g) in aorta and age (years).  
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Figure 29  Relationship between Pb levels (µg/g) in aorta and age (years). 
 
Figure 30  Relationship between Se levels (µg/g) in aorta and age (years). 
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4.4 HEALTHY INDIVIDUALS VS INDIVIDUALS WITH CVD 
Next tables summarize the results obtained for “healthy” individuals and for individuals 
that fulfil the criteria for inclusion in the CVD group. Tables 24 and 25 regards the 
determination in kidney tissue (cortex and medulla results); table 26 and 27 regards the 
determination in aorta tissue (with and without atheroma plaque).  
Table 24  Concentration (µg/g) of the elements in the kidney tissue of healthy individuals 
Kidney Cu Zn Se Cd Pb 
N 41 41 39 41 41 
Mean 7.96 142.1 5.48 55.04 0.41 
SD 3.71 81.60 5.35 44.32 0.45 
Median 8.35 125.3 4.51 39.73 0.26 
Minimum 1.44 16.93 1.39 4.47 0.04 
Maximum 15.94 300.0 35.32 179.5 2.56 
 
Table 25  Concentration (µg/g) of the elements in the kidney tissue of individuals with CVD. 
Kidney Cu Zn Se Cd Pb 
N 44 45 40 45 45 
Mean 5.61 115.7 3.90 50.35 0.24 
SD 3.82 88.42 2.80 41.51 0.16 
Median 4.57 85.54 2.66 43.32 0.22 
Minimum 1.28 18.46 0.83 0.03 0.02 
Maximum 16.63 373.4 11.90 198.5 0.66 
 
Table 26  Concentration (µg/g) of the elements in aorta tissue of healthy individuals. 
Aorta Cu Zn Se Cd Pb 
N 38 38 34 37 38 
Mean 4.48 105.3 4.46 1.92 2.79 
SD 2.69 56.56 2.14 4.13 3.06 
Median 3.96 92.09 4.35 0.35 1.93 
Minimum 1.10 24.54 1.34 0.01 0.05 
Maximum 14.69 350.2 10.53 23.28 12.42 
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Table 27  Concentration (µg/g) of the elements in aorta tissue of individuals with CVD. 
Aorta Cu Zn Se Cd Pb 
N 43 43 38 42 43 
Mean 3.18 106.3 3.59 0.36 3.22 
SD 1.32 69.01 2.45 0.95 2.83 
Median 3.13 88.03 3.14 0.05 2.22 
Minimum 1.26 21.22 0.47 0.01 0.10 
Maximum 6.26 358.0 14.17 4.63 14.19 
 
Individuals with CVD showed significant lower levels of Cu than healthy subjects in both 
the kidney (5.61±3.82 vs 7.96±3.71 µg/g; p<0.01) and aorta tissue (3.18±1.32 vs 
4.48±2.69 µg/g; p≤0.01) (Figure 31). Which is in disagreement with the hypothesis that Cu 
is a risk factor for CVD (38). 
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Figure 31  Copper levels (g/g) in kidney and aorta tissue in healthy individuals (n=19) and 
individuals with CVD (n=23); **p≤0.01 
A similar finding was observed for Cd and Pb. Individuals with CVD showed lower levels 
of Cd in aorta tissue (0.36±0.95 vs 1.92±4.13 µg/g; p≤0.05) (Figure 32) and lower levels of 
Pb in the kidney than healthy individuals (0.24±0.16 µg/g vs 0.41±0.45 µg/g; p≤0,05). 
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Figure 32  Cadmium levels (g/g) in aorta tissue of healthy individuals (n=19) and individuals with 
CVD (n=23) *p≤0.05 
H e a lth y C V D
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
K
id
n
e
y
 [
P
b
] 
( 
g
/g
)
*
 
Figure 33  Lead levels (g/g) in kidney in healthy individuals (n=19) and individuals with CVD 
(n=23); *p≤0.05 
 
Selenium was the only exception to this general tendency. Individuals with CVD showed 
lower levels than healthy subjects in both the kidney (3.90±2.80 vs 5.48±5.35 µg/g; 
p≤0.05) and aorta tissue (3.59± 2.45 vs 4.46±2.14 µg/g; p≤0.05) (Figure 34), which in 
accordance with current evidence from prospective studies that supports a modest 
inverse association between Se levels and the risk of heart disease (54). 
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Figure 34  Selenium levels (g/g) in kidney and aorta tissue from healthy individuals (n=19) and 
individuals with CVD (n=23); *p≤0.05 
Zinc showed no difference between both groups (healthy individuals and individuals with CVD). 
There are numerous conflicting studies regarding Zn and CVD. Via nitric oxide pathway, 
Zn deficiency may cause hypertension, an important risk factor for atherosclerosis. In 
addition, the antioxidant action of Zn prevents oxidation of LDL and consequently stops 
the main mechanism of atherogenesis (85). However, increased levels of Zn may 
enhance atherosclerosis via increased oxidant species generation and decreased HDL 
levels (60).  
Several studies corroborate the hypothesis that Zn deficiency may be a risk factor for 
atherosclerosis in animals (57, 58, 86). Recently, Islamoglu et al. (87) showed significantly 
decreased serum levels of Zn and Cu in human patients with atherosclerosis compared to 
the control group. 
Although there are strong reasons to admit that trace element imbalances may be 
involved in the aetiology of CVD, epidemiological studies have been inconsistent. 
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CHAPTER 5 
CONCLUSIONS and FUTURE RESEARCH 
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CONCLUSIONS AND FUTURE RESEARCH 
This work aimed to study the link between trace element imbalances and CVD. A direct 
approach (i.e., the analysis of the “target” tissues themselves) was used, instead of the 
usually performed analysis of body fluids (blood, urine), which is a particular and 
distinctive feature of this work. It is widely assumed that this may be a potentially more 
conclusive approach. 
The direct study of the changes of three important trace elements (Zn, Cu and Se) and 
two important “heavy metals” (Cd and Pb) in kidney tissue (cortex and medulla) and aorta 
wall (both with and without atheroma plaque) was performed. 
Data obtained clearly show that: 
 The two kidney regions (cortex and medulla) present significantly different levels of Zn 
and Cd (higher in cortex).  
 In kidney medulla a gender-related difference was observed for Pb (higher values in 
men). Smoking habits leads to increased levels of Zn, Cd and Pb.  
 In kidney cortex smoking habits showed to induce significantly increases levels of Cd. 
 In both kidney regions a slight tendency for an age-related increase in trace elements 
levels was observed. However, Cd in kidney cortex showed an interesting behaviour: 
after a increase up to 50 years old, a subsequent decreased was observed. 
 For aorta without plaque no gender or smoking habits-related differences were found 
for the five elements.  
 In aorta with plaque, smokers showed significantly decreased Zn levels. 
Aorta with plaque showed higher levels of Zn and lower levels of Se than aorta without 
plaque. 
The comparison between results from “healthy” individuals and individuals with CVD 
showed: 
 Significantly lower levels of Se in both kidney and aorta tissues, indicating a potential 
cardio-protector role for Se.  
 However Cu (in both kidney and aorta tissues), Cd (in aorta) and Pb (in the kidney) 
were also significantly lower in CVD, which is may be considered as unexpected 
findings, requiring further investigation. 
The data presented should be considered as preliminary results. However, they seem to 
corroborate the hypothesis that trace elements play an important role in CVD and 
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important trace element imbalances may occur in tissues. A main question is whether 
these changes are a cause or a consequence of CVDs. 
Further investigation of trace elements imbalances in body tissues and its correlation with 
CVD must be expanded to include more individuals, more elements and more tissues. 
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ATTACHMENT 
Data of the studied subjects 
 
Age 
Range 
Cause of death Gender Age Smoker CVD Residence 
20-29 Traumatic Brain Injury F 20 No No Maia 
Traumatic Brain Injury M 22 No No Valongo 
Eating disorders F 25 No No  Matosinhos 
Traumatic Brain Injury M 26 No ? Gaia 
Traumatic Brain Injury M 28 No No  Valongo 
30-39 Arrhythmia F 33 No No Matosinhos 
Traumatic Brain Injury M 34 No No Vila Nova de 
Famalicão 
Acute Myocardial Infarction M 37 Former 
smoker 
Yes Porto 
Chest trauma by firearm F 39 No No Gaia 
Suicide by stab F 39 ? No Gaia 
40-49 Asphyxia from hanging M 42 ? No Vila do Conde 
Traumatic Brain Injury M 43 Yes No Alfandega da Fé 
Left ventricular hypertrophy M 43 No No Vila do Conde 
Alcohol intoxication associated 
with aspiration of vomit 
M 44 Yes No  Gondomar 
Traumatic Brain Injury M 44 Yes No Felgueiras 
? M 46 ? Yes Santo Tirso 
Left hypertrophic cardiomyopathy F 47 Yes ? Vila do Conde 
Drug intoxication F 47 No No Porto 
Acute Myocardial Infarction M 48 Yes Yes Gondomar 
50-59 Bronchopneumonia M 50 No Yes ? 
Acute Myocardial Infarction M 50 Yes Yes Porto 
Asphyxia from hanging M 51 ? ? Porto 
Asphyxiation due to aspiration of 
foreign body 
M 52 No ? Gaia 
Asphyxia from hanging M 53 ? No Santo Tirso 
Acute Myocardial Infarction M 54 Yes Yes Gaia 
Hepatorrenal syndrome M 55 Yes Yes Gondomar 
Pneumonia F 56 Yes No Gaia 
Traumatic Brain Injury F 57 ? No Porto 
Acute Myocardial Infarction M 59 Yes Yes Matosinhos 
60-69 Traumatic Brain Injury M 64 No Yes Mirandela 
Acute Myocardial Infarction M 65 Yes Yes Gondomar 
Asphyxia from hanging M 67 ? Yes Gaia 
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? F 67 No Yes Matosinhos 
Acute Myocardial Infarction M 68 No Yes Maia 
Pulmonary embolism F 69 No No Gondomar 
70-79 Traumatic Brain Injury M 70 Former 
smoker 
? Matosinhos 
? M 71 ? ? Gaia 
? F 71 No No Gaia 
Pneumonia M 73 No No Barcelos 
Sepsis F 74 No Yes Porto 
Asphyxia from hanging M 74 ? No Gondomar 
Pulmonary embolism F 74 No Yes Porto 
Asphyxia from hanging F 76 ? ? Gaia 
Acute Myocardial Infarction F 79 Yes No Vila do Conde 
? M 79 Former 
smoker 
? Vila do Conde 
Traumatic injuries M 79 No Yes Porto 
80-89 Traumatic injuries M 82 No Yes Gondomar 
Multiorgan failure due to 
pneumonia 
F 83 No Yes Marco de 
Canaveses 
Stroke F 84 No Yes Gaia 
Abdominal infection F 85 No ? Vila do Conde 
Traumatic Brain Injury M 86 No Yes Chaves 
Traumatic Brain Injury F 87 No Yes Porto 
≥90 ? F 91 No Yes Porto 
Pulmonary embolism F 93 No Yes Porto 
 
